Entry in the ADHD drugs market: Welfare impact of generics and me-toos
Recent years have seen the growing popularity of drugs designed to treat attention deficit hyperactivity disorder (ADHD), and the number of patients, scripts, and revenues has been steadily increasing. By the mid-1990s there were already several branded drugs marketed for this disorder, as well as numerous generic formulations. With the expansion of the market in the late 1990s and early 2000s, new formulations (the so called `me-too' drugs) entered and caused dramatic changes in the distribution of market shares among available drugs. Using detailed sales data on psychostimulant drugs used to treat ADHD, we are able to identify and measure substitution patterns across a range of drugs. We find that the demand for ADHD drugs is fairly elastic and there are significant substitution possibilities among these drugs. Using estimates from demand parameters, we show that the first-time introduction of a generic drug can have large welfare gains due to the expansion of the market to price sensitive consumers. Additionally, the welfare gains due to the introduction of me-too drugs vary by the novelty of the drug, and for significantly new varieties can be larger than those of the introduction of a generic. Our results bear policy implications for both the speed with which new drugs are approved for marketing as well as for actions among pharmaceutical firms that may delay the entry of a generic drug.
|Date of creation:||May 2009|
|Date of revision:|
|Contact details of provider:|| Postal: |
Web page: http://www.coss.fsu.edu/economics/
More information through EDIRC
|Order Information:|| Email: |
When requesting a correction, please mention this item's handle: RePEc:fsu:wpaper:wp2009_05_01. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Dmitry Ryvkin)
If references are entirely missing, you can add them using this form.